Scholar Rock
NASDAQ · SRRK·Cambridge, MA·Mid-cap·Phase 3
Clinical-stage biopharma developing therapies that target latent growth factors. Lead asset apitegromab is a myostatin inhibitor in Phase 3 for spinal muscular atrophy (SMA) with positive SAPPHIRE results, and in Phase 2 for obesity preserving lean mass.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Scholar Rock January 2026 Corporate Presentation | Corporate overview | January 13, 2026 | 31 |